Observational studyNeurology(R) neuroimmunology & neuroinflammation2021
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.
Leoni Rolfes et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
70 papers cite itlatest 60 shown
this paperpooled ittrialcites it